<DOC>
	<DOCNO>NCT00734032</DOCNO>
	<brief_summary>The primary objective study examine effect SB-480848 plasma lipoprotein associate phospholipase A2 ( Lp-PLA2 ) activity dyslipidemic patient 4-week treatment SB-480848 .</brief_summary>
	<brief_title>A Phase II Clinical Study SB-480848 Dyslipidemic Patients</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Inclusion criterion : Dyslipidemic subject currently undergo statin therapy change lipidlowering therapy dose 4 week prior randomization Exclusion criterion : 1 . Recent ( i.e. , &lt; 6 month prior screen ) CV event and/or vascular procedure define : A ) STelevation MI nonSTelevation MI B ) Unstable angina C ) Coronary revascularization [ ( percutaneous coronary intervention ( PCI ) coronary artery bypass graft ( CABG ) ] D ) Stroke etiology E ) Peripheral arterial disease critical limb ischemia ( rest pain ischemic skin lesion , either ulcer gangrene ) F ) Resuscitated cardiac arrest 2 . Planned CABG plan PCI plan major noncardiac surgery within study period 3 . No measurable LpPLA2 activity plasma ( &lt; 10 nmol/min/mL ) screen 4 . Change lipidlowering medication , regimen dosage 4 week prior randomization 5 . Poorly control dyslipidemia ( LDLc &gt; =160 mg/dL ) screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>SB-480848</keyword>
	<keyword>Dyslipidaemia</keyword>
</DOC>